Acurx Pharmaceuticals (ACXP) director awarded 2,150 stock options as board pay

Rhea-AI Filing Summary

Acurx Pharmaceuticals director James J. Donohue received a stock option grant covering 2,150 shares of common stock as board compensation. The option has an exercise price of $2.36 per share, vests on April 20, 2027, and expires on April 20, 2036. Following the grant, he holds 2,150 stock options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Donohue James J.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	2,150	$0.00	--

Holdings After Transaction: Stock Option — 2,150 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Stock options granted: 2,150 options Exercise price: $2.36 per share Underlying shares: 2,150 shares +3 more

6 metrics

Stock options granted 2,150 options Grant related to board service

Exercise price $2.36 per share Strike price for option grant

Underlying shares 2,150 shares Common stock underlying options

Vesting date April 20, 2027 Date options become exercisable

Expiration date April 20, 2036 Option term end date

Options after transaction 2,150 options Total derivative holdings reported

Key Terms

Stock Option, Director Compensation Policy, vest, exercise price

4 terms

Stock Option financial

"security_title: "Stock Option" with underlying common stock shares"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

Director Compensation Policy financial

"granted pursuant to the Issuer's Director Compensation Policy"

vest financial

"The shares subject to the options shall vest on April 20, 2027"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

exercise price financial

"conversion_or_exercise_price: "2.3600" per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Donohue James J.

(Last) (First) (Middle)

C/O ACURX PHARMACEUTICALS, INC.,

259 LIBERTY AVENUE

(Street)

STATEN ISLAND NEW YORK 10305

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Acurx Pharmaceuticals, Inc. [ ACXP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$2.36	04/20/2026		A		2,150(1)		04/20/2027	04/20/2036	Common Stock	2,150	$0	2,150	D

Explanation of Responses:

1. This stock option award is related to service on the Issuer's board of directors granted pursuant to the Issuer's Director Compensation Policy. The shares subject to the options shall vest on April 20, 2027.

	/s/ Kostantinos Skordalos, Power of Attorney For: James J. Donohue	04/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Acurx Pharmaceuticals (ACXP) report for James J. Donohue?

Acurx Pharmaceuticals reported that director James J. Donohue received a stock option grant for 2,150 shares. The award is compensation for board service, not an open-market purchase, and gives the right to buy common shares at a set exercise price.

What are the key terms of James J. Donohue’s new ACXP stock options?

The stock option covers 2,150 shares of Acurx common stock with a $2.36 exercise price. The award vests on April 20, 2027, and expires on April 20, 2036, defining when the director can exercise and when the right ends.

Is the Acurx (ACXP) Form 4 transaction a stock purchase or a grant?

The Form 4 reports a grant of stock options, not a market purchase. Code “A” indicates a grant or award acquisition, giving the director rights to buy shares later at $2.36, subject to the vesting schedule.

When do the newly granted Acurx (ACXP) options to James J. Donohue vest?

The options granted to James J. Donohue vest on April 20, 2027. Vesting means he must remain eligible under the Director Compensation Policy until that date before he can exercise the options for Acurx common shares.

How many Acurx (ACXP) stock options does James J. Donohue hold after this filing?

After this grant, the Form 4 shows James J. Donohue directly holding 2,150 stock options. These options correspond to 2,150 underlying Acurx common shares and reflect his derivative position reported in this specific insider filing.